Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page.

This Week’s Highlights

Visana Health secures $10.1M in seed funding to scale its virtual-first women’s healthcare model.

Mercury 13 launches a $100M fund to acquire women’s football clubs.

Delphinus raises $12M for its 3D Whole Breast Ultrasounds Tomography System to invest in further expansion.

Pregnancy care company Nuvo Groupmerges with LAMF Global Ventures in SPAC deal.

Female-led EverBlumelaunches with a mission to support 40 Million Americans struggling with substance abuse.

Fertillyintroduces Europe’s first home fertility test leveraging dry blood method.

HANX expands its offering; launches new supplements for pregnancy and menopause.

Hey Janeexpands its virtual health services beyond abortion.

FEMSelect unveils positive study results for its EnPlace Pelvic Organ Prolapse Repair System.

New research suggests MysteryVibe‘s Crescendo 2 could aid in treating female sexual arousal disorder.

UCL to launch the UK’s first menopause education program.

NIH allocates $24M to set up Maternal Health Research Centers of Excellence in the US.

In the Know

COVID-19 Infections and Vaccinations Temporarily Impact Menstrual Cycle, Clue Data Study Reveals (Femtech Insider)

Femtech‘s untapped potential is a trillion-dollar wakeup call to investors (FastCompany)

‘Dirty red’: how periods have been stigmatised through history to the modern day (The Conversation)

Woman receives sister’s womb in first UK transplant (BBC)

Some Americans Take on Side Hustles for Fertility Benefits (WSJ)

The Next Frontier for Corporate Benefits: Menopause (New York Times)

Technology could improve pregnancy care for low-income patients – if health systems can pay for it (STAT News)

Show CommentsClose Comments

Leave a comment